Tislelizumab with chemoradiotherapy for stage IIIC2 cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether adding tislelizumab to standard chemotherapy and radiation works better as first treatment for stage IIIC2 cervical cancer. It aims to improve how well the cancer responds and controls the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- Your cervical cancer was confirmed under a microscope as one of these types: squamous, adenocarcinoma, or adenosquamous
- You have stage IIIC2 cervical cancer (2018 FIGO stage) and it has not spread to distant sites (no metastasis)
- You have at least one measurable tumor area that can be tracked on scans
- Your health status is good enough for treatment (ECOG 0–1) and you have enough blood and organ function
- You have not had certain cancer medicines or immune-related treatments before, and you do not have major immune or uncontrolled health problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (nimotuzumab and tislelizumab) plus radiation for women whose cervical cancer has come back or spread to a few places in the body. The goal is to see if this treatment can shrink tumors and help patients live longer.
This study tests whether adding the drug nimotuzumab to standard chemoradiotherapy (radiation plus chemo) and then continuing maintenance therapy works better for locally advanced cervical cancer (stages IB3 to IVA) than chemoradiotherapy alone.
This trial tests adding the immunotherapy drug Zimberelimab to standard chemoradiation after surgery for locally advanced cervical cancer. It aims to see if this combination helps prevent the cancer from coming back.
This trial tests a drug called adebrelimab combined with standard chemotherapy and radiation for cervical cancer. It may be an option for people with stage IIB to IVA cervical cancer who have not had prior treatment.
This study tests whether combining immunotherapy with chemotherapy, followed by radiation plus immunotherapy, can work better than standard treatment for cervical cancer. It aims to help patients whose cancer has not spread yet.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy as a first treatment for people with stage IIIB or IIIC non-small cell lung cancer. The goal is to see if this approach can shrink the tumor before any other treatment.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.